ERBB2 and gastroesophageal junction adenocarcinoma: Untreated, locally advanced or metastatic HER2 negative G/GEJ adenocarcinoma. 67. 8% male, 39% with age ≥ 65 years, 37% ECOG 0, 33% from Asia, 25% from Western Europe, Israel, North America, and Australia, and 41% from the rest of the world.